|
Compound class:
Antibody
Comment: PF-07062119 is a bispecific T cell-engaging (BiTE) monoclonal antibody that is being developed by Pfizer [1]. It simultaneously binds to CD3ε on T cells and GUCY2C-positive cancer cells.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use  |
| PF-07062119 has commenced Phase 1 Safety and Tolerability evaluation in patients with selected advanced/metastatic gastrointestinal tumours. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04171141 | Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors. | Phase 1 Interventional | Pfizer | ||
